Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients-authors' response.

Wu, Tzong-YowTzong-YowWuCHEN PAO-YUJANN-TAY WANGLIU WANG-DAYEE-CHUN CHENSHAN-CHWEN CHANG2025-02-182025-02-182024-12-02https://scholars.lib.ntu.edu.tw/handle/123456789/725302en[SDGs]SDG3Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients-authors' response.editorial10.1093/jac/dkae35739373636